InsiderTrades.com logo
Hans T. Schambye net worth and biography
  • LinkedIn
  • Phone
  • Website

Hans Schambye Biography and Net Worth

CEO of Galecto
Hans Schambye is a seasoned biotech entrepreneur with extensive experience in drug discovery and development. Previously, Hans served as the Chief Executive Officer of ReceptIcon from 2006 to 2009 and as the CEO of Gastrotech Pharma A/S from 2004 to 2006. Before joining Gastrotech, he was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Prior to this he had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Hans holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.

What is Hans T. Schambye's net worth?

The estimated net worth of Hans T. Schambye is at least $11,617.74 as of January 3rd, 2025. Dr. Schambye owns 3,397 shares of Galecto stock worth more than $11,618 as of March 30th. This net worth approximation does not reflect any other investments that Dr. Schambye may own. Additionally, Dr. Schambye receives an annual salary of $700,130.00 as CEO at Galecto. Learn More about Hans T. Schambye's net worth.

How old is Hans T. Schambye?

Dr. Schambye is currently 58 years old. There are 2 older executives and no younger executives at Galecto. Learn More on Hans T. Schambye's age.

What is Hans T. Schambye's salary?

As the CEO of Galecto, Inc., Dr. Schambye earns $700,130.00 per year. Learn More on Hans T. Schambye's salary.

How do I contact Hans T. Schambye?

The corporate mailing address for Dr. Schambye and other Galecto executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Galecto can also be reached via phone at 45-7070-5210. Learn More on Hans T. Schambye's contact information.

Has Hans T. Schambye been buying or selling shares of Galecto?

Within the last three months, Hans T. Schambye has sold $7,509.60 in shares of Galecto stock. Most recently, Hans T. Schambye sold 1,341 shares of the business's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $5.60, for a transaction totalling $7,509.60. Following the completion of the sale, the chief executive officer now directly owns 3,397 shares of the company's stock, valued at $19,023.20. Learn More on Hans T. Schambye's trading history.

Who are Galecto's active insiders?

Galecto's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Galecto's active insiders.

Are insiders buying or selling shares of Galecto?

In the last year, insiders at the sold shares 2 times. They sold a total of 1,602 shares worth more than $8,979.03. The most recent insider tranaction occured on January, 3rd when CFO Lori Firmani sold 261 shares worth more than $1,469.43. Insiders at Galecto own 11.9% of the company. Learn More about insider trades at Galecto.

Information on this page was last updated on 1/3/2025.

Hans T. Schambye Insider Trading History at Galecto

See Full Table

Hans T. Schambye Buying and Selling Activity at Galecto

This chart shows Hans T Schambye's buying and selling at Galecto by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$7.51ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10k-$5k$0$5k$10kTotal Insider BuyingTotal Insider Selling

Galecto Company Overview

Galecto logo
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $3.42
Low: $3.00
High: $3.53

50 Day Range

MA: $4.65
Low: $3.42
High: $6.70

2 Week Range

Now: $3.42
Low: $3.00
High: $20.25

Volume

65,899 shs

Average Volume

74,633 shs

Market Capitalization

$4.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18